FRONTIER BIOTECHNOLOGIES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.78 CNY | -2.31% |
|
+3.04% | -31.65% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 84.74M 11.73M 979M | Sales 2023 | 114M 15.81M 1.32B | Capitalization | 3.72B 514M 42.94B |
|---|---|---|---|---|---|
| Net income 2022 | -357M -49.42M -4.13B | Net income 2023 | -329M -45.54M -3.8B | EV / Sales 2022 | 64.9 x |
| Net cash position 2022 | 962M 133M 11.12B | Net cash position 2023 | 561M 77.71M 6.49B | EV / Sales 2023 | 27.6 x |
| P/E ratio 2022 |
-17.6
x | P/E ratio 2023 |
-11.3
x | Employees | 395 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.97% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.31% | ||
| 1 week | +3.04% | ||
| Current month | +3.04% | ||
| 1 month | +0.89% | ||
| 3 months | +13.38% | ||
| 6 months | -38.36% | ||
| Current year | -31.65% |
1 week
6.59
7.10
1 month
5.377.10
Current year
5.0910.06
1 year
5.0913.16
3 years
5.0927.88
5 years
5.0935.53
10 years
5.0935.53
| Managers | Title | Age | Since |
|---|---|---|---|
Rong Jian Lu
FOU | Founder | 62 | 15/13/15 |
Dong Xie
FOU | Founder | 58 | 15/13/15 |
Chang Jin Wang
FOU | Founder | 66 | 15/13/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang Jin Wang
FOU | Founder | 66 | 15/13/15 |
Guang Ji Wang
BRD | Director/Board Member | 71 | 24/22/24 |
Yuan Tao Cao
BRD | Director/Board Member | 43 | 26/18/26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 6.78 | -2.31% | 3,259,622 |
| 09/24/09 | 6.94 | -0.29% | 3,700,517 |
| 08/24/08 | 6.96 | +2.20% | 5,265,288 |
| 07/24/07 | 6.81 | -0.58% | 2,556,191 |
End-of-day quote Shanghai S.E., May 10, 2024
More quotes
Frontier Biotechnologies Inc is a China-based company engaged in research and development, production and sales of innovative drugs. The Company's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The Company conducts its businesses within the China market and to overseas markets.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -31.65% | 351M | |
| +7.91% | 72.81B | |
| +12.64% | 9.13B | |
| -10.56% | 5.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 688221 Stock